Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
- DOI
- 10.1038/s41375-020-01111-2
- Published
- 2021 Feb
- Container
- Leukemia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41375-020-01111-2,
title = {Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.},
author = {Kantarjian HM and Hughes TP and Larson RA and Kim DW and Issaragrisil S and le Coutre P and Etienne G and Boquimpani C and Pasquini R and Clark RE and Dubruille V and Flinn IW and Kyrcz-Krzemien S and Medras E and Zanichelli M and Bendit I and Cacciatore S and Titorenko K and Aimone P and Saglio G and Hochhaus A},
year = {2021},
journal = {Leukemia},
doi = {10.1038/s41375-020-01111-2},
url = {https://doi.org/10.1038/s41375-020-01111-2}
}RIS
TY - JOUR TI - Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. AU - Kantarjian HM AU - Hughes TP AU - Larson RA AU - Kim DW AU - Issaragrisil S AU - le Coutre P AU - Etienne G AU - Boquimpani C AU - Pasquini R AU - Clark RE AU - Dubruille V AU - Flinn IW AU - Kyrcz-Krzemien S AU - Medras E AU - Zanichelli M AU - Bendit I AU - Cacciatore S AU - Titorenko K AU - Aimone P AU - Saglio G AU - Hochhaus A PY - 2021 JO - Leukemia DO - 10.1038/s41375-020-01111-2 UR - https://doi.org/10.1038/s41375-020-01111-2 ER -
APA
HM, K., TP, H., RA, L., DW, K., S, I., P, L. C., G, E., C, B., R, P., RE, C., V, D., IW, F., S, K., E, M., M, Z., I, B., S, C., K, T., P, A., G, S., & A, H. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.. Leukemia. https://doi.org/10.1038/s41375-020-01111-2
Source records
- pubmed · retrieved 2026-09-26T14:08:31.429Z